New hope for tough lung cancer? early trial tests novel drug combo
NCT ID NCT06931626
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new oral drug called NMS-03305293, combined with the chemotherapy temozolomide, in 10 people with relapsed small cell lung cancer. The main goal is to check safety and tolerability, while also looking for signs that the tumors shrink. All participants have already tried standard treatments and have limited options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NMS-03305293 (a new PARP inhibitor drug) combined with temozolomide (a chemotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for people with relapsed small cell lung cancer who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety, not effectiveness. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States